# Risankizumab

## Skyrizi 75mg/0.83mL pre-filled syringe

##### 臨採

| TAH Drug Code      | [**ISKY**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISKY)                                                                                                                                                                                                         |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.                                                                                                                                                                                           |
| Dosing             | SC, 150 mg at week 0 and week 4, followed by every 12 weeks.                                                                                                                                                                                                                     |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                    |
| Contraindications  | Specific contraindications have not been determined                                                                                                                                                                                                                              |
| Adverse Effects    | Common Dermatologic: Injection site reaction (1.5% ), Tinea (1.1% ) Immunologic: Antibody development (24%% ) Neurologic: Headache (3.5% ) Respiratory: Upper respiratory infection (13% ) Other: Fatigue (2.5% ) Serious Immunologic: Infectious disease (22.1% ), Tuberculosis |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                          |
| Lactation          | Unknown                                                                                                                                                                                                                                                                          |

